HD-OPM Archive
Hashtags

#niacin

23 posts

Niacin can cut Lp(a) (one member saw 40% with 1500 mg) but has no outcome proof

Jan 19, 2024 · Louis Nervegna ♥ 15 · 💬 37 Lp(a)

Louis explains niacin can be effective at lowering Lp(a) and is still used by some cardiologists, with one group member reporting a 40% Lp(a) drop on 1500 mg. He gives tips for reducing the harmless flush and explains sustained-release formulations. He warns niacin has not been shown in large RCTs to reduce heart attacks, strokes or mortality, and two large trials found no added benefit on top of high-dose statins but more side effects.

Niacin for CVD prevention: no reason to use it given proven options, says the poster

Sep 19, 2026 · Louis Nervegna ♥ 21 · 💬 11 PCSK9, ezetimibe & newer drugs

The poster gives his opinion that niacin is only better than nothing and no longer worth taking for cardiovascular prevention given proven alternatives. He would never combine it with high-dose statins, citing two large trials with no added benefit and more side effects, and no longer sees a role in high Lp(a) after the HORIZON trial failure.

Blood NAD levels do not fall with age, so commercial NAD blood tests are useless

Oct 24, 2026 · Louis Nervegna ♥ 15 · 💬 5 Aging & longevity

A new Nature Metabolism study found whole-blood NAD+ levels stay stable with age across seven independent human cohorts. Louis explains blood NAD mainly reflects recent vitamin B3 intake, so commercial NAD blood tests are not meaningful, while tissue NAD levels may matter but cannot be commercially measured. There is still no convincing clinical evidence NR or NMN supplements slow human aging.

HDL and ApoA-I raising therapies repeatedly failed, so HDL is probably not directly causal

Mar 11, 2024 · Louis Nervegna ♥ 6 · 💬 9 ↩ 22 LDL, ApoB & lipid panel

Louis reviews why HDL or ApoA-I is probably not causal for heart disease. CETP inhibitor trials failed (ILLUMINATE with torcetrapib was stopped for harm; dal-OUTCOMES with dalcetrapib and ACCELERATE with evacetrapib showed no benefit), as did fibrate and niacin trials and CSL112 infusions, and Mendelian randomization agrees. He proposes HDL and ApoA-I mainly act as a proxy for insulin sensitivity, which is the real causal factor.

Bale-Doneen protocol: aggressive multi-drug risk management reduced carotid IMT

Dec 03, 2023 · Gokhan Can ♥ 11 · 💬 3 ↩ 2 Plaque, CAC & CT angiography

Describes the Bale and Doneen approach to reversing plaque: lifestyle counseling, regular imaging and biomarker testing, statin-based lipid control with ezetimibe or niacin, SBP under 120, low-dose aspirin, insulin sensitizers and anti-inflammatories. In the 2016 community-based paper, carotid IMT measures fell markedly over a median of 3 years.

Case: carotid plaque regression with salmon, niacin and low-dose rosuvastatin

Dec 23, 2023 · Louis Nervegna ♥ 13 · 💬 3 Plaque, CAC & CT angiography

Louis shares a video by Dr. Ford Brewer describing his own plaque reversal. He ate salmon daily, added niacin and low-dose rosuvastatin and switched from an ARB to an ACE inhibitor, with a major decrease in carotid plaque volume and CIMT arterial age falling from 72 to 52. It is a single self-reported case in a video from a clinic that also sells services and supplements.

Nicotinic acid (vitamin B3) may prevent or treat glaucoma, possibly via NAD

Dec 10, 2023 · Louis Nervegna ♥ 12 · 💬 2 ↩ 2 Supplements & vitamins

Louis notes growing evidence that nicotinic acid, the niacin form used to lower cholesterol, may prevent or treat glaucoma, a disease with no effective treatment that causes irreversible blindness. The mechanism likely involves NAD. Most studies used nicotinic acid, so it is unclear how nicotinamide, NR or NMN compare. This is an eye-health tangent, supported by a video.

High-dose niacin shows early promise in glioblastoma: 82% progression-free at 6 months

Oct 12, 2026 · Louis Nervegna ♥ 6 Cancer

A small phase 1 pilot trial of high-dose, controlled-release niacin added to standard chemotherapy and radiotherapy for glioblastoma reported 82% of patients progression-free at six months. The poster notes the doses resemble those once used for high cholesterol and that results used historical controls, so a randomized phase 2 trial is ongoing.